Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant ...
JAK inhibitors, a new class of tsDMARDs, have shown superior efficacy in RCTs for RA compared to other biologics. Real-world studies highlight JAK inhibitors' benefits in clinical disease activity, ...
Here are the top 5 inflammation pieces of 2025; stay up-to-date with all the inflammation content from The American Journal ...
Please provide your email address to receive an email when new articles are posted on . The 8-year long-term extension found no new safety signals with filgotinib for RA treatment. Disease response ...
Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 trials.
Previous, smaller studies had found that patients tended to gain weight while on the Janus kinase (JAK) inhibitor tofacitinib. This study, funded by tofacitinib's manufacturer, analyzed data from more ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. MIAMI BEACH, Fla. — Janus kinase inhibitors are an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results